Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
AssigneesLudwig Institute for Cancer, Institut Pasteur
InventorsGilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
Life of this patent
Estimating the term…
Abstract
An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
Claims23
An immunogenic composition comprising a recombinant protein, wherein the recombinant protein comprises a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen.
11-22. (canceled)
A method of treating a patient with cancer comprising (1) administering a immunogenic composition to the patient, wherein the immunogenic composition comprises a recombinant protein, wherein the recombinant protein comprises a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen, and (2) inducing a T cell response in the patient.
28-33. (canceled)
A method of treating a patient with cancer comprising (1) administering an immunogenic composition to the patient, wherein the immunogenic composition comprises a vector expressing a recombinant protein, wherein the recombinant protein comprises a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen, and (2) inducing a T cell response in the patient.
39-44. (canceled)
Dependencies are inferred from the claim text.